Chemeq commercial trial succeeds
AN independent commercial trial of Chemeq’s polymeric antimicrobial product for pigs has been completed at a New Zealand pig production farm with successful results.
The treatment, in comparison with the leading antibiotic apramycin or the control resulted in: improved weight gain; improvement in the feed conversion ration; reduced feed consumption and a 53 per cent reduction in additional antibiotic injections during treatment to combat uncontrolled post-wean colibacillosis than ampamycin-treated pigs.
The trial involved 21 day old weaner pigs.
Chemeq chairman Graham Melrose said the success followed a similar one from an earlier trial at an Australian poultry producer.
The company is in the final stages of commissioning its plant.